Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDPP4HTR1BHTR1D
The experimentally established mechanism targets of Ellagic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.70 |
| ▸ | MEN1 | O00255 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | RECQL | P46063 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.70 |
| ▸ | HPGD | P15428 | 5/20 | 0.70 |
| ▸ | BLM | P54132 | 4/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.70 |
| ▸ | MAOA | P21397 | 4/20 | 0.70 |
| ▸ | PKLR | P30613 | 2/20 | 0.70 |
| ▸ | GALNT2 | Q10471 | 2/20 | 0.70 |
| ▸ | APEX1 | P27695 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | CA12 | O43570 | 2/20 | 0.70 |
| ▸ | CA1 | P00915 | 2/20 | 0.70 |
| ▸ | TP53 | P04637 | 2/20 | 0.70 |
| ▸ | CA7 | P43166 | 2/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ellagic Acid SCHEMBL9483887 | 0.88 | KDM4E (0.74) | KDM4EMEN1MAPTRECQLKMT2A | |
| Ellagic Acid SCHEMBL4429252 | 0.86 | KDM4E (0.77) | KDM4EMEN1MAPTRECQLKMT2A | |
| Ellagic Acid SCHEMBL1645767 | 0.83 | KDM4E (1.00) | KDM4EMEN1MAPTRECQLKMT2A | |
| Ellagic Acid SCHEMBL29439360 | 0.83 | KDM4E (1.00) | KDM4EMEN1MAPTRECQLKMT2A | |
| Ellagic Acid SCHEMBL20429 | 0.83 | KDM4E (1.00) | KDM4EMEN1MAPTRECQLKMT2A | |
| Ellagic Acid SCHEMBL30475160 | 0.83 | KDM4E (1.00) | KDM4EMEN1MAPTRECQLKMT2A | |
| Ellagic Acid SCHEMBL9792365 | 0.83 | KDM4E (0.72) | KDM4EMEN1MAPTRECQLKMT2A | |
| Ellagic Acid SCHEMBL3801270 | 0.82 | KDM4E (0.82) | KDM4EMEN1MAPTRECQLKMT2A | |
| Ellagic Acid SCHEMBL8686551 | 0.82 | KDM4E (0.96) | KDM4EMEN1MAPTRECQLKMT2A | |
| Ellagic Acid SCHEMBL8686700 | 0.82 | KDM4E (0.96) | KDM4EMEN1MAPTRECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023176783-A1 | SOLID COMPOSITION | 第一三共ヘルスケア株式会社 | 2023-09-21 | — | — | WO | disclosed |
| US-20160339263-A1 | SKIN LIGHTENER IN PHOTOTHERAPY | MERCK PATENT GMBH (DE) | 2016-11-24 | — | — | US | disclosed |
| EP-1586315-B1 | SKIN LIGHTENING COMPOSITION | DAIICHI SANKYO HEALTHCARE CO (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-20060142382-A1 | Skin lightening composition | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-06-29 | — | — | US | disclosed |
| EP-1586315-A1 | SKIN LIGHTENING COMPOSITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160339263-A1 | SKIN LIGHTENER IN PHOTOTHERAPY | TYR, MC1R, CUTA | KDM4E 3556/4885MEN1 2810/4885MAPT 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.